You just read:

European Medicines Agency Begins Evaluation of Marketing Application for Sublingual Sufentanil 30 mcg Tablet (ARX-04) for Moderate-to-Severe Acute Pain

News provided by

AcelRx Pharmaceuticals, Inc.

Mar 28, 2017, 07:00 ET